한글목차

세계 과민성대장증후군(IBS) 및 염증성 장질환(IBD) 치료제 시장 규모는 2025년 333억 달러에서 예측 기간 동안 9.6%의 CAGR(연평균 성장률)을 기록하며 2030년 말에는 526억 달러로 성장할 것으로 예상됩니다.

북미 시장은 2025년 146억 달러에서 예측 기간 동안 8.2%의 CAGR로 성장하여 2030년 말에는 216억 달러에 달할 것으로 예상됩니다. 유럽 시장은 2025년 90억 달러에서 예측 기간 동안 CAGR 10.6%로 성장하여 2030년 말에는 148억 달러에 달할 것으로 예상됩니다.

세계의 과민성대장증후군(IBS) 및 염증성 장질환(IBD) 치료제 시장을 조사했으며, 시장 개요, 시장 영향요인 및 시장 기회 분석, 시장 규모 추정 및 예측, 각종 부문별·지역별 상세 분석 등의 정보를 정리하여 전해드립니다.

목차

제1장 주요 요약

• 시장 전망
• 조사 범위
• 시장 요약
• 신흥 기술
• 부문 분석
• 지역 분석
• 결론

제2장 시장 개요

• 개요
• 염증성 장질환
• 과민성대장증후군
• Porter's Five Forces 분석
• 미국 관세의 영향
• 거시경제 요인 분석
• 인구구조와 고령화
• 약가 관련 정부 정책

제3장 시장 역학

• 시장 역학
• 시장 촉진요인
• 소화기 질환 유병률 증가
• 생물학적 제제 및 바이오시밀러의 진입 증가
• 시장 억제요인
• 생물학적 제제의 부작용 및 상한 효과
• 다른 소화기 질환과의 중복
• 대체 치료제 사용
• 시장 기회
• 자가 투약 약품
• 맞춤형 치료제

제4장 규제 현황

• IBS 및 IBD 치료제의 규제 측면
• 미국
• EU
• 아시아태평양

제5장 신흥 기술 및 파이프라인 분석

• 중요 포인트
• 신흥 기술
• 신규 표적 기반 저분자 의약품
• 마이크로바이옴 기반 치료제
• 고도의 복합 치료
• 신약개발을 위한 AI
• 파이프라인 분석

제6장 시장 세분화 분석

• 세분화 내역
• 시장 분석 : 질환별
• 중요 포인트
• 과민성대장증후군
• 염증성 장질환
• 시장 분석 : 약제 종류별 시장 분석
• 중요 포인트
• 과민성대장증후군
• 염증성 장질환
• 지리적 분류
• 시장 분석 : 지역별
• 중요 포인트
• 북미
• 유럽
• 아시아태평양
• 남미
• 중동 및 아프리카

제7장 경쟁 정보

• 중요 포인트
• 산업 구조
• IBD 치료제 시장 기업 점유율 분석
• IBS 치료제 시장 경쟁사 점유율 분석
• 전략 분석

제8장 IBS 및 IBD 시장의 지속가능성 : ESG 관점

• ESG : 소개
• ESG 리스크 평가
• 결론

제9장 부록

• 조사 방법
• 정보 출처
• 약어
• 기업 개요
• ABBVIE INC.
• AMGEN INC.
• ASTRAZENECA
• BAYER AG
• BIOGEN
• BRISTOL-MYERS SQUIBB CO.
• GILEAD SCIENCES INC.
• IRONWOOD
• JOHNSON & JOHNSON SERVICES INC.
• LILLY
• MERCK & CO. INC.
• PFIZER INC.
• SANOFI
• TAKEDA PHARMACEUTICAL CO. LTD.
• UCB S.A.
• Emerging Start-ups/ Market Disruptors

영문목차

The global market for irritable bowel syndrome (IBS) and inflammatory bowel disease (IBD) therapeutics is expected to grow from $33.3 billion in 2025 and is projected to reach $52.6 billion by the end of 2030, at a compound annual growth rate (CAGR) of 9.6% during the forecast period of 2025 to 2030.

The North American market for IBS and IBD therapeutics is expected to grow from $14.6 billion in 2025 and is projected to reach $21.6 billion by the end of 2030, at a CAGR of 8.2% during the forecast period of 2025 to 2030.

The European market for IBS and IBD therapeutics is expected to grow from $9 billion in 2025 and is projected to reach $14.8 billion by the end of 2030, at a CAGR of 10.6% during the forecast period of 2025 to 2030.

Report Scope

The report provides an overview of the global irritable bowel syndrome (IBS) and inflammatory bowel disease (IBD) therapeutics market and analyzes market trends. It includes global revenue ($ million) for the base year 2024, estimated data for 2025 and forecast data from 2026 through 2030. The market is segmented into irritable bowel syndrome and inflammatory bowel disease based on disease type. The IBS therapeutics segment is further segmented based on symptom type and drug class.

• By symptom type, IBS therapeutics include IBS with constipation (IBS-C), IBS with diarrhea (IBS-D) and IBS with mixed symptoms (IBS-M).
• By drug class, IBS therapeutics include guanylate cyclase-C agonists, antibiotics, laxatives, antispasmodics and others.

The IBD therapeutics segment is further segmented based on type and drug class.

• By type, IBD therapeutics include ulcerative colitis and Crohn's disease.
• By drug class, therapeutics for IBD include interleukin inhibitors, integrin antagonists, TNF inhibitors, JAK (Janus kinases) inhibitors, and others

The report also focuses on regional market segmentation. The regions covered in this study include North America, Europe, Asia-Pacific, South America and the Middle East and Africa (MEA), focusing on significant countries in these regions. The report includes an analysis of the competitive landscape, which provides the ranking and share of key businesses in the global IBS and IBD therapeutics market. A dedicated section of company profiles providing details about leading market enterprises is also included.

The scope does not cover alternative therapies for IBS and IBD, such as herbal medicine, dietary supplements and behavioral therapies.

Report Includes

• 142 data tables and 54 additional tables
• Analysis of the global market for irritable bowel syndrome (IBS) and inflammatory bowel disease (IBD) therapeutics
• Analyses of global market trends, with historic revenue data from 2022 to 2024, estimates for 2025, and projected CAGRs through 2030
• Estimates of the market's size and revenue prospects, along with a corresponding market share analysis by symptom type, drug class, type, and region
• Facts and figures pertaining to market dynamics, technological advances, regulations and the impact of macroeconomic factors
• Insights derived from Porter's Five Forces model, as well as global supply chain analysis
• Patent analysis, featuring key granted and published patents
• Overview of sustainability trends and ESG developments, with emphasis on consumer attitudes, as well as the ESG risk ratings and practices of leading companies
• Analysis of the industry structure, including companies' market shares and rankings, strategic alliances, M&A activity and a venture funding outlook
• Profiles of the leading companies, including AbbVie Inc., Johnson & Johnson Services Inc., Ironwood Pharmaceuticals, Takeda Pharmaceuticals, and Amgen Inc.

Table of Contents

Chapter 1 Executive Summary

• Market Outlook
• Scope of Report
• Market Summary
• Emerging Technologies
• Segmental Analysis
• Regional Analysis
• Conclusion

Chapter 2 Market Overview

• Overview
• Inflammatory Bowel Disease
• Irritable Bowel Syndrome
• Porter's Five Forces Analysis in the IBS and IBD Therapeutics Market
• Potential of New Entrants (Low to Moderate)
• Bargaining Power of Suppliers (Low)
• Bargaining Power of Buyers (High)
• Threat of Substitute Products (Moderate)
• Industry Rivalry (High)
• Impact of U.S. Tariffs
• Macroeconomic Factor Analysis
• Population Demographics and Aging Populations
• Government Policies on Drug Prices

Chapter 3 Market Dynamics

• Market Dynamics
• Market Drivers
• Rising Prevalence of Gastrointestinal Disorders
• Increasing Entry of Biologics and Biosimilars
• Market Restraints
• Side Effects and Ceiling Impact of Biologics
• Overlap with Other GI Disorders
• Use of Alternative Treatment Approaches
• Market Opportunities
• Self-Administered Drugs
• Personalized Therapies

Chapter 4 Regulatory Landscape

• Regulatory Aspects of IBS and IBD Therapeutics
• The U.S.
• European Union
• Asia-Pacific

Chapter 5 Emerging Technologies and Pipeline Analysis

• Key Takeaways
• Emerging Technologies
• Novel Target-Based Small-Molecule Drugs
• Microbiome-Based Therapeutics
• Advanced Combination Treatments
• AI for Drug Discovery
• Pipeline Analysis

Chapter 6 Market Segmentation Analysis

• Segmentation Breakdown
• Market Analysis by Disease
• Key Takeaways
• Irritable Bowel Syndrome
• Inflammatory Bowel Disease
• Market Analysis by Drug Class
• Key Takeaways
• Irritable Bowel Syndrome
• Inflammatory Bowel Disease
• Geographic Breakdown
• Market Analysis by Region
• Key Takeaways
• North America
• Europe
• Asia-Pacific
• South America
• Middle East and Africa

Chapter 7 Competitive Intelligence

• Key Takeaways
• Industry Structure
• Company Share Analysis of the IBD Therapeutics Market
• Competitive Share Analysis of the IBS Therapeutics Market
• Strategic Analysis

Chapter 8 Sustainability in the IBS and IBD Market: An ESG Perspective

• Introduction to ESG
• ESG Risk Ratings
• Conclusion

Chapter 9 Appendix

• Methodology
• Sources
• Abbreviations
• Company Profiles
• ABBVIE INC.
• AMGEN INC.
• ASTRAZENECA
• BAYER AG
• BIOGEN
• BRISTOL-MYERS SQUIBB CO.
• GILEAD SCIENCES INC.
• IRONWOOD
• JOHNSON & JOHNSON SERVICES INC.
• LILLY
• MERCK & CO. INC.
• PFIZER INC.
• SANOFI
• TAKEDA PHARMACEUTICAL CO. LTD.
• UCB S.A.
• Emerging Start-ups/ Market Disruptors